Johnson & Johnson Q3 2026 GAAP earnings fall 95.9%
The quarter paired 5.9% reported sales growth with $0.09 diluted EPS, while 2026 sales and adjusted EPS guidance midpoints increased.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Johnson & Johnson reported third-quarter 2026 sales of $25.399 billion, up 5.9% from a year earlier; operational sales growth was 6.0%. GAAP net earnings were $210 million and diluted EPS was $0.09, down 95.9% and 95.8%, respectively. The company said EPS reflected a one-time special charge for the proposed talc litigation resolution, the Firefly Bio acquisition and Sail Biomedicines collaboration. Adjusted net earnings were $6.339 billion, down 6.8%, and adjusted diluted EPS was $2.59, down 7.5%.
Johnson & Johnson raised its 2026 guidance: estimated reported sales are $101.0 billion–$101.4 billion, with a $101.2 billion midpoint, and adjusted diluted EPS is $11.05–$11.15, with an $11.10 midpoint. The adjusted EPS midpoint increased by $0.06, corresponding to 2.9% growth at the midpoint. Innovative Medicine sales rose 7.7% to $16.757 billion, while MedTech sales rose 2.5% to $8.642 billion. During the quarter, the company completed its Firefly Bio acquisition; it also reported FDA approval of IMAAVY for warm autoimmune hemolytic anemia and market authorization for its OTTAVA robotic surgical system.
1 point · 0 major0 major · 2 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointReported Q3 sales grew 5.9% to $25.399 billion.
Negative
- Moderate pointGAAP net earnings fell 95.9% to $210 million.
- Moderate pointAdjusted net earnings declined 6.8% to $6.339 billion.
Filing Explained
The filing says Johnson & Johnson’s supply-chain restructuring is expected to cost
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Reported sales: $25.399 billion
GAAP net earnings: $210 million
Diluted EPS: $0.09
+4 more
7 metrics
Reported sales
$25.399 billion
Third quarter 2026; up 5.9% year over year
GAAP net earnings
$210 million
Third quarter 2026; down 95.9% year over year
Diluted EPS
$0.09
Third quarter 2026; down 95.8% year over year
Adjusted net earnings
$6.339 billion
Third quarter 2026; down 6.8% year over year
Adjusted diluted EPS
$2.59
Third quarter 2026; down 7.5% year over year
Estimated reported sales guidance
$101.0 billion–$101.4 billion; midpoint $101.2 billion
2026 guidance updated in October 2026
Adjusted diluted EPS guidance
$11.05–$11.15; midpoint $11.10
2026 guidance; midpoint increased by $0.06
Key Terms
adjusted operational sales growth, translational currency, special items, Free Cash Flow
4 terms
adjusted operational sales growth financial
"Adjusted operational sales growth excludes"
translational currency financial
"excluding the impact of translational currency"
special items financial
"may exclude such items as intangible asset amortization expense"
Special items are unusual or infrequent gains or losses that a company reports separately from its regular operating profit, such as restructuring costs, asset write-downs, legal settlements, or one-time gains from selling a business. Investors pay attention because these items can make reported profits look better or worse than the company’s ongoing performance—like a homeowner’s one-off roof repair affecting a single month’s budget but not the household’s regular income and expenses.
Free Cash Flow financial
"defined as cash flow from operating activities, less additions to property"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Earnings Snapshot
Reported sales: $25.399 billion · Guidance included
Third quarter 2026 ended September 27, 2026
Reported sales
$25.399 billion
+5.9%
Net earnings
$210 million
-95.9%
Diluted EPS
$0.09
-95.8%
Adjusted net earnings
$6.339 billion
-6.8%
Adjusted diluted EPS
$2.59
-7.5%
Guidance
2026 estimated reported sales of $101.0 billion–$101.4 billion, midpoint $101.2 billion; adjusted diluted EPS of $11.05–$11.15, midpoint $11.10. The adjusted EPS midpoint increased by $0.06.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Johnson & Johnson's updated 2026 guidance?
Johnson & Johnson's estimated reported sales guidance is $101.0 billion–$101.4 billion, with a $101.2 billion midpoint; adjusted diluted EPS guidance is $11.05–$11.15, with an $11.10 midpoint. The adjusted EPS midpoint increased by $0.06 from the July 29, 2026 guidance.
Why was Johnson & Johnson's Q3 2026 diluted EPS $0.09?
The company said third-quarter diluted EPS of $0.09 reflected a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 2.02 Results of operations and financial condition
On October 13, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 27, 2026.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |||||||
99.1 | Press Release dated October 13, 2026 for the period ended September 27, 2026 | |||||||
99.2 | Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months | |||||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | |||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 13, 2026
| JOHNSON & JOHNSON | |||||
(Registrant) | |||||
By: | /s/ Robert J. Decker, Jr. | ||||
Robert J. Decker, Jr. Controller (Principal Accounting Officer) | |||||
Exhibit 99.1
Media contact: media-relations@its.jnj.com | Investor contact: investor-relations@its.jnj.com | |||||||
For immediate release
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
•2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
•2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals
•Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint
•Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer
New Brunswick, N.J. (October 13, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Overall financial results
Q3 | ||||||||||||||||||||
($ in Millions, except EPS) | 2026 | 2025 | % Change | |||||||||||||||||
Reported Sales | $25,399 | $23,993 | 5.9 | % | ||||||||||||||||
Net Earnings | $210 | $5,152 | (95.9) | % | ||||||||||||||||
EPS (diluted) | $0.09 | $2.12 | (95.8) | % | ||||||||||||||||
Q3 | ||||||||||||||||||||
Non-GAAP* ($ in Millions, except EPS) | 2026 | 2025 | % Change | |||||||||||||||||
Operational Sales1,2 | 6.0 | % | ||||||||||||||||||
Adjusted Operational Sales1,3 | 6.1 | % | ||||||||||||||||||
Adjusted Net Earnings1,4 | $6,339 | $6,801 | (6.8) | % | ||||||||||||||||
Adjusted EPS (diluted)1,4 | $2.59 | $2.80 | (7.5) | % | ||||||||||||||||
Free Cash Flow5,6 | ~$15,100 | $14,226 | ||||||||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
4Excludes intangible amortization expense and special items
5Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
6Third-quarter YTD 2026 is estimated as of October 13, 2026
Note: values may have been rounded
Regional sales results
Q3 | % Change | |||||||||||||||||||
($ in Millions) | 2026 | 2025 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | ||||||||||||||
U.S. | $14,959 | $13,708 | 9.1 | % | 9.1 | — | 9.1 | |||||||||||||
International | 10,440 | 10,285 | 1.5 | 1.8 | (0.3) | 1.9 | ||||||||||||||
Worldwide | $25,399 | $23,993 | 5.9 | % | 6.0 | (0.1) | 6.1 | |||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q3 | % Change | |||||||||||||||||||
($ in Millions) | 2026 | 2025 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | ||||||||||||||
Innovative Medicine | $16,757 | $15,563 | 7.7 | % | 7.9 | (0.2) | 8.0 | |||||||||||||
MedTech | 8,642 | 8,430 | 2.5 | 2.5 | 0.0 | 2.5 | ||||||||||||||
Worldwide | $25,399 | $23,993 | 5.9 | % | 6.0 | (0.1) | 6.1 | |||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Third-Quarter 2026 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.
MedTech
MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.
Full-year 2026 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) | October 2026 | July 29, 2026 | ||||||
Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 6.4% – 6.8% / 6.6% | 6.2% – 6.8% / 6.5% | ||||||
Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9% | $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% | ||||||
Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% | ||||||
Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0% | $10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4% | ||||||
Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point | $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9% | $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3% | ||||||
1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2Non-GAAP financial measure; excludes the impact of translational currency
3Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only)
4Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.
Regulatory | Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses1 | Press Release | |||||||||
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients | Press Release | ||||||||||
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer | Press Release | ||||||||||
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System | Press Release | ||||||||||
Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy | Press Release | ||||||||||
Data Releases | New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis1 | Press Release | |||||||||
Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy1 | Press Release | ||||||||||
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) | Press Release | ||||||||||
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study | Press Release | ||||||||||
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma | Press Release | ||||||||||
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma | Press Release | ||||||||||
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study | Press Release | ||||||||||
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 | Press Release | ||||||||||
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer | Press Release | ||||||||||
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 | Press Release | ||||||||||
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma | Press Release | ||||||||||
Other | New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause1 | Press Release | |||||||||
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September | Press Release | ||||||||||
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation | Press Release | ||||||||||
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset | Press Release | ||||||||||
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation | Press Release | ||||||||||
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Exhibit 99.2
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | THIRD QUARTER | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by geographic area | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
U.S. | $14,959 | 13,708 | 9.1 | % | 9.1 | — | ||||||||||||||
Europe | 5,405 | 5,440 | (0.6) | 1.0 | (1.6) | |||||||||||||||
Western Hemisphere excluding U.S. | 1,385 | 1,231 | 12.5 | 8.0 | 4.5 | |||||||||||||||
Asia-Pacific, Africa | 3,650 | 3,614 | 1.0 | 1.0 | 0.0 | |||||||||||||||
International | 10,440 | 10,285 | 1.5 | 1.8 | (0.3) | |||||||||||||||
Worldwide | $25,399 | 23,993 | 5.9 | % | 6.0 | (0.1) | ||||||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | NINE MONTHS | ||||||||||||||||
| Percent Change | |||||||||||||||||
| Sales to customers by geographic area | 2026 | 2025 | Total | Operations | Currency | ||||||||||||
U.S. | $42,822 | 39,557 | 8.3 | % | 8.3 | — | |||||||||||
Europe | 16,979 | 15,937 | 6.5 | 2.3 | 4.2 | ||||||||||||
Western Hemisphere excluding U.S. | 3,987 | 3,604 | 10.6 | 4.5 | 6.1 | ||||||||||||
Asia-Pacific, Africa | 10,983 | 10,531 | 4.3 | 3.6 | 0.7 | ||||||||||||
International | 31,949 | 30,072 | 6.2 | 3.0 | 3.2 | ||||||||||||
Worldwide | $74,771 | 69,629 | 7.4 | % | 6.0 | 1.4 | |||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | THIRD QUARTER | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by segment of business | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
Innovative Medicine | ||||||||||||||||||||
U.S. | $ | 10,447 | 9,402 | 11.1 | % | 11.1 | — | |||||||||||||
International | 6,310 | 6,161 | 2.4 | 3.0 | (0.6) | |||||||||||||||
| 16,757 | 15,563 | 7.7 | 7.9 | (0.2) | ||||||||||||||||
MedTech | ||||||||||||||||||||
U.S. | 4,512 | 4,306 | 4.8 | 4.8 | — | |||||||||||||||
International | 4,130 | 4,124 | 0.1 | 0.1 | 0.0 | |||||||||||||||
| 8,642 | 8,430 | 2.5 | 2.5 | 0.0 | ||||||||||||||||
U.S. | 14,959 | 13,708 | 9.1 | 9.1 | — | |||||||||||||||
International | 10,440 | 10,285 | 1.5 | 1.8 | (0.3) | |||||||||||||||
Worldwide | $ | 25,399 | 23,993 | 5.9 | % | 6.0 | (0.1) | |||||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | NINE MONTHS | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by segment of business | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
Innovative Medicine | ||||||||||||||||||||
U.S. | $ | 29,297 | 26,655 | 9.9 | % | 9.9 | — | |||||||||||||
International | 19,270 | 17,983 | 7.2 | 3.6 | 3.6 | |||||||||||||||
| 48,567 | 44,638 | 8.8 | 7.4 | 1.4 | ||||||||||||||||
MedTech | ||||||||||||||||||||
U.S. | 13,525 | 12,902 | 4.8 | 4.8 | — | |||||||||||||||
International | 12,679 | 12,089 | 4.9 | 2.2 | 2.7 | |||||||||||||||
| 26,204 | 24,991 | 4.9 | 3.5 | 1.4 | ||||||||||||||||
U.S. | 42,822 | 39,557 | 8.3 | 8.3 | — | |||||||||||||||
International | 31,949 | 30,072 | 6.2 | 3.0 | 3.2 | |||||||||||||||
Worldwide | $ | 74,771 | 69,629 | 7.4 | % | 6.0 | 1.4 | |||||||||||||
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| (Unaudited; in Millions Except Per Share Figures) | THIRD QUARTER | ||||||||||||||||
| 2026 | 2025 | Percent Increase (Decrease) | |||||||||||||||
| Amount | Percent to Sales | Amount | Percent to Sales | ||||||||||||||
| Sales to customers | $ | 25,399 | 100.0 | $ | 23,993 | 100.0 | 5.9 | ||||||||||
| Cost of products sold | 8,097 | 31.9 | 7,303 | 30.4 | 10.9 | ||||||||||||
| Gross Profit | 17,302 | 68.1 | 16,690 | 69.6 | 3.7 | ||||||||||||
| Selling, marketing and administrative expenses | 6,285 | 24.7 | 5,922 | 24.7 | 6.1 | ||||||||||||
| Research and development expense | 4,652 | 18.3 | 3,672 | 15.3 | 26.7 | ||||||||||||
| In-process research and development impairments | 339 | 1.4 | — | — | |||||||||||||
| Interest (income) expense, net | 31 | 0.1 | 18 | 0.1 | |||||||||||||
| Other (income) expense, net | 5,780 | 22.8 | (478) | (2.0) | |||||||||||||
| Restructuring | 181 | 0.7 | 63 | 0.3 | |||||||||||||
| Earnings before provision for taxes on income | 34 | 0.1 | 7,493 | 31.2 | (99.5) | ||||||||||||
| (Benefit from)/Provision for taxes on income | (176) | (0.7) | 2,341 | 9.7 | (107.5) | ||||||||||||
| Net earnings | $ | 210 | 0.8 | $ | 5,152 | 21.5 | (95.9) | ||||||||||
| Net earnings per share (Diluted) | $ | 0.09 | $ | 2.12 | (95.8) | ||||||||||||
| Average shares outstanding (Diluted) | 2,448.6 | 2,428.6 | |||||||||||||||
| Effective tax rate | (517.6) | % | 31.2 | % | |||||||||||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||||||||||
Earnings before provision for taxes on income | $ | 7,672 | 30.2 | $ | 8,436 | 35.2 | (9.1) | ||||||||||
Net earnings | $ | 6,339 | 25.0 | $ | 6,801 | 28.3 | (6.8) | ||||||||||
Net earnings per share (Diluted) | $ | 2.59 | $ | 2.80 | (7.5) | ||||||||||||
Effective tax rate | 17.4 | % | 19.4 | % | |||||||||||||
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| (Unaudited; in Millions Except Per Share Figures) | NINE MONTHS | ||||||||||||||||
| 2026 | 2025 | Percent Increase (Decrease) | |||||||||||||||
| Amount | Percent to Sales | Amount | Percent to Sales | ||||||||||||||
| Sales to customers | $ | 74,771 | 100.0 | $ | 69,629 | 100.0 | 7.4 | ||||||||||
| Cost of products sold | 24,254 | 32.4 | 22,288 | 32.0 | 8.8 | ||||||||||||
| Gross Profit | 50,517 | 67.6 | 47,341 | 68.0 | 6.7 | ||||||||||||
| Selling, marketing and administrative expenses | 18,751 | 25.1 | 16,923 | 24.3 | 10.8 | ||||||||||||
| Research and development expense | 11,832 | 15.8 | 10,413 | 15.0 | 13.6 | ||||||||||||
| In-process research and development impairments | 375 | 0.5 | — | — | |||||||||||||
| Interest (income) expense, net | 136 | 0.2 | (62) | (0.1) | |||||||||||||
| Other (income) expense, net | 6,405 | 8.6 | (7,692) | (11.1) | |||||||||||||
| Restructuring | 247 | 0.3 | 144 | 0.2 | |||||||||||||
| Earnings before provision for taxes on income | 12,771 | 17.1 | 27,615 | 39.7 | (53.8) | ||||||||||||
| Provision for taxes on income | 1,792 | 2.4 | 5,927 | 8.6 | (69.8) | ||||||||||||
| Net earnings | $ | 10,979 | 14.7 | $ | 21,688 | 31.1 | (49.4) | ||||||||||
| Net earnings per share (Diluted) | $ | 4.49 | $ | 8.94 | (49.8) | ||||||||||||
| Average shares outstanding (Diluted) | 2,445.8 | 2,424.8 | |||||||||||||||
| Effective tax rate | 14.0 | % | 21.5 | % | |||||||||||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||||||||||
Earnings before provision for taxes on income | $ | 24,153 | 32.3 | $ | 24,635 | 35.4 | (2.0) | ||||||||||
Net earnings | $ | 20,034 | 26.8 | $ | 20,206 | 29.0 | (0.9) | ||||||||||
Net earnings per share (Diluted) | $ | 8.19 | $ | 8.33 | (1.7) | ||||||||||||
Effective tax rate | 17.1 | % | 18.0 | % | |||||||||||||
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
| THIRD QUARTER | NINE MONTHS | |||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Net Earnings, after tax- as reported | $210 | $5,152 | $10,979 | $21,688 | ||||||||||||||||||||||
| Pre-tax Adjustments | ||||||||||||||||||||||||||
| Litigation related | 5,519 | 15 | 6,116 | (6,894) | ||||||||||||||||||||||
| Intangible Asset Amortization expense | 1,240 | 1,048 | 3,732 | 3,435 | ||||||||||||||||||||||
Restructuring related 1 | 195 | 168 | 533 | 302 | ||||||||||||||||||||||
| Orthopaedics separation related | 369 | — | 746 | — | ||||||||||||||||||||||
| Acquisition, integration and divestiture related | (34) | 97 | 142 | 475 | ||||||||||||||||||||||
| (Gains)/losses on securities | 10 | (387) | (262) | (327) | ||||||||||||||||||||||
| IPR&D impairments | 339 | — | 375 | — | ||||||||||||||||||||||
| Other | — | 2 | — | 29 | ||||||||||||||||||||||
| Tax Adjustments | ||||||||||||||||||||||||||
Tax impact on special item adjustments 2 | (1,677) | (168) | (2,469) | 826 | ||||||||||||||||||||||
| Tax legislation and other tax related | 168 | 874 | 142 | 672 | ||||||||||||||||||||||
| Adjusted Net Earnings, after tax | $6,339 | $6,801 | $20,034 | $20,206 | ||||||||||||||||||||||
| Average shares outstanding (Diluted) | 2,448.6 | 2,428.6 | 2,445.8 | 2,424.8 | ||||||||||||||||||||||
| Adjusted net earnings per share (Diluted) | $2.59 | $2.80 | $8.19 | $8.33 | ||||||||||||||||||||||
| Operational adjusted net earnings per share (Diluted) | $2.61 | $8.04 | ||||||||||||||||||||||||
Notes:
1In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Third quarter 2026 actual vs. 2025 actual
| Segments | ||||||||||||||||||||||||||
| Innovative Medicine | MedTech | Total | ||||||||||||||||||||||||
| WW As Reported | 7.7 | % | 2.5 | % | 5.9 | % | ||||||||||||||||||||
| U.S. | 11.1 | % | 4.8 | % | 9.1 | % | ||||||||||||||||||||
| International | 2.4 | % | 0.1 | % | 1.5 | % | ||||||||||||||||||||
| WW Currency | (0.2) | 0.0 | (0.1) | |||||||||||||||||||||||
| U.S. | — | — | — | |||||||||||||||||||||||
| International | (0.6) | 0.0 | (0.3) | |||||||||||||||||||||||
| WW Operational | 7.9 | % | 2.5 | % | 6.0 | % | ||||||||||||||||||||
| U.S. | 11.1 | % | 4.8 | % | 9.1 | % | ||||||||||||||||||||
| International | 3.0 | % | 0.1 | % | 1.8 | % | ||||||||||||||||||||
| All Other Acquisitions and Divestitures (A&D) | 0.1 | 0.0 | 0.1 | |||||||||||||||||||||||
| U.S. | 0.0 | 0.0 | 0.0 | |||||||||||||||||||||||
| International | 0.2 | 0.0 | 0.1 | |||||||||||||||||||||||
| WW Adjusted Operational Ex A&D | 8.0 | % | 2.5 | % | 6.1 | % | ||||||||||||||||||||
| U.S. | 11.1 | % | 4.8 | % | 9.1 | % | ||||||||||||||||||||
| International | 3.2 | % | 0.1 | % | 1.9 | % | ||||||||||||||||||||
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Nine months 2026 actual vs. 2025 actual
| Segments | ||||||||||||||||||||
| Innovative Medicine | MedTech | Total | ||||||||||||||||||
| WW As Reported | 8.8 | % | 4.9 | % | 7.4 | % | ||||||||||||||
| U.S. | 9.9 | % | 4.8 | % | 8.3 | % | ||||||||||||||
| International | 7.2 | % | 4.9 | % | 6.2 | % | ||||||||||||||
| WW Currency | 1.4 | 1.4 | 1.4 | |||||||||||||||||
| U.S. | — | — | — | |||||||||||||||||
| International | 3.6 | 2.7 | 3.2 | |||||||||||||||||
| WW Operational | 7.4 | % | 3.5 | % | 6.0 | % | ||||||||||||||
| U.S. | 9.9 | % | 4.8 | % | 8.3 | % | ||||||||||||||
| International | 3.6 | % | 2.2 | % | 3.0 | % | ||||||||||||||
| Caplyta | (0.6) | (0.4) | ||||||||||||||||||
| U.S. | (1.0) | (0.7) | ||||||||||||||||||
| International | 0.0 | 0.0 | ||||||||||||||||||
| All Other Acquisitions and Divestitures (A&D) | 0.1 | 0.1 | 0.1 | |||||||||||||||||
| U.S. | 0.0 | 0.1 | 0.0 | |||||||||||||||||
| International | 0.2 | 0.0 | 0.1 | |||||||||||||||||
| WW Adjusted Operational Ex A&D | 6.9 | % | 3.6 | % | 5.7 | % | ||||||||||||||
| U.S. | 8.9 | % | 4.9 | % | 7.6 | % | ||||||||||||||
| International | 3.8 | % | 2.2 | % | 3.1 | % | ||||||||||||||
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2) | |||||||||||||||||||||||
| ONCOLOGY | |||||||||||||||||||||||
| US | $ | 4,267 | 3,468 | 23.0 | % | 23.0 | % | — | % | ||||||||||||||
| Intl | 3,335 | 3,060 | 9.0 | 9.5 | (0.5) | ||||||||||||||||||
| WW | 7,602 | 6,529 | 16.4 | 16.7 | (0.3) | ||||||||||||||||||
| DARZALEX | |||||||||||||||||||||||
| US | 2,528 | 2,088 | 21.1 | 21.1 | — | ||||||||||||||||||
| Intl | 1,711 | 1,584 | 8.0 | 8.5 | (0.5) | ||||||||||||||||||
| WW | 4,239 | 3,672 | 15.4 | 15.6 | (0.2) | ||||||||||||||||||
| CARVYKTI | |||||||||||||||||||||||
| US | 472 | 396 | 19.4 | 19.4 | — | ||||||||||||||||||
| Intl | 238 | 128 | 85.3 | 84.1 | 1.2 | ||||||||||||||||||
| WW | 710 | 524 | 35.5 | 35.2 | 0.3 | ||||||||||||||||||
| TECVAYLI | |||||||||||||||||||||||
| US | 236 | 115 | * | * | — | ||||||||||||||||||
| Intl | 77 | 62 | 24.0 | 25.9 | (1.9) | ||||||||||||||||||
| WW | 312 | 177 | 76.6 | 77.3 | (0.7) | ||||||||||||||||||
| TALVEY | |||||||||||||||||||||||
| US | 112 | 85 | 31.6 | 31.6 | — | ||||||||||||||||||
| Intl | 59 | 37 | 62.9 | 66.9 | (4.0) | ||||||||||||||||||
| WW | 171 | 122 | 40.9 | 42.1 | (1.2) | ||||||||||||||||||
| RYBREVANT / LAZCLUZE | |||||||||||||||||||||||
| US | 201 | 136 | 47.9 | 47.9 | — | ||||||||||||||||||
| Intl | 119 | 61 | 94.5 | 98.3 | (3.8) | ||||||||||||||||||
| WW | 320 | 198 | 62.3 | 63.5 | (1.2) | ||||||||||||||||||
| ERLEADA | |||||||||||||||||||||||
| US | 423 | 378 | 11.8 | 11.8 | — | ||||||||||||||||||
| Intl | 600 | 558 | 7.7 | 7.7 | 0.0 | ||||||||||||||||||
| WW | 1,023 | 936 | 9.4 | 9.4 | 0.0 | ||||||||||||||||||
| IMBRUVICA | |||||||||||||||||||||||
| US | 145 | 211 | (31.6) | (31.6) | — | ||||||||||||||||||
| Intl | 420 | 483 | (13.2) | (12.6) | (0.6) | ||||||||||||||||||
| WW | 563 | 695 | (18.8) | (18.4) | (0.4) | ||||||||||||||||||
OTHER ONCOLOGY(3) | |||||||||||||||||||||||
| US | 149 | 61 | * | * | — | ||||||||||||||||||
| Intl | 111 | 147 | (24.4) | (23.9) | (0.5) | ||||||||||||||||||
| WW | 262 | 207 | 26.3 | 26.7 | (0.4) | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| IMMUNOLOGY | |||||||||||||||||||||||
| US | $ | 2,804 | 2,676 | 4.8 | % | 4.8 | % | — | % | ||||||||||||||
| Intl | 1,417 | 1,493 | (5.1) | (4.8) | (0.3) | ||||||||||||||||||
| WW | 4,221 | 4,168 | 1.3 | 1.4 | (0.1) | ||||||||||||||||||
| TREMFYA | |||||||||||||||||||||||
| US | 1,772 | 989 | 79.1 | 79.1 | — | ||||||||||||||||||
| Intl | 624 | 434 | 43.7 | 43.4 | 0.3 | ||||||||||||||||||
| WW | 2,396 | 1,424 | 68.3 | 68.2 | 0.1 | ||||||||||||||||||
| SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||
| US | 269 | 309 | (13.2) | (13.2) | — | ||||||||||||||||||
| Intl | 299 | 377 | (20.6) | (20.3) | (0.3) | ||||||||||||||||||
| WW | 568 | 687 | (17.3) | (17.1) | (0.2) | ||||||||||||||||||
| REMICADE | |||||||||||||||||||||||
| US | 258 | 326 | (20.8) | (20.8) | — | ||||||||||||||||||
US Exports(4) | 12 | 19 | (37.1) | (37.1) | — | ||||||||||||||||||
| Intl | 124 | 132 | (6.2) | (7.5) | 1.3 | ||||||||||||||||||
| WW | 394 | 476 | (17.3) | (17.6) | 0.3 | ||||||||||||||||||
| STELARA | |||||||||||||||||||||||
| US | 368 | 1,022 | (64.0) | (64.0) | — | ||||||||||||||||||
| Intl | 349 | 549 | (36.5) | (35.5) | (1.0) | ||||||||||||||||||
| WW | 716 | 1,570 | (54.4) | (54.0) | (0.4) | ||||||||||||||||||
| OTHER IMMUNOLOGY | |||||||||||||||||||||||
| US | 126 | 12 | * | * | — | ||||||||||||||||||
| Intl | 21 | 0 | * | * | * | ||||||||||||||||||
| WW | 147 | 12 | * | * | * | ||||||||||||||||||
| NEUROSCIENCE | |||||||||||||||||||||||
| US | 1,733 | 1,367 | 26.8 | 26.8 | — | ||||||||||||||||||
| Intl | 642 | 658 | (2.4) | (1.7) | (0.7) | ||||||||||||||||||
| WW | 2,375 | 2,024 | 17.3 | 17.6 | (0.3) | ||||||||||||||||||
| SPRAVATO | |||||||||||||||||||||||
| US | 559 | 405 | 37.9 | 37.9 | — | ||||||||||||||||||
| Intl | 66 | 53 | 22.7 | 21.4 | 1.3 | ||||||||||||||||||
| WW | 624 | 459 | 36.1 | 36.0 | 0.1 | ||||||||||||||||||
| CAPLYTA | |||||||||||||||||||||||
| US | 398 | 240 | 66.1 | 66.1 | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 398 | 240 | 66.1 | 66.1 | — | ||||||||||||||||||
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||
| US | 739 | 664 | 11.4 | 11.4 | — | ||||||||||||||||||
| Intl | 258 | 267 | (3.0) | (2.4) | (0.6) | ||||||||||||||||||
| WW | 998 | 929 | 7.3 | 7.5 | (0.2) | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CONCERTA / methylphenidate | |||||||||||||||||||||||
| US | $ | 6 | 14 | (56.3) | % | (56.3) | % | — | % | ||||||||||||||
| Intl | 138 | 127 | 8.1 | 8.9 | (0.8) | ||||||||||||||||||
| WW | 143 | 140 | 2.1 | 2.9 | (0.8) | ||||||||||||||||||
| OTHER NEUROSCIENCE | |||||||||||||||||||||||
| US | 32 | 46 | (30.6) | (30.6) | — | ||||||||||||||||||
| Intl | 180 | 210 | (14.3) | (13.1) | (1.2) | ||||||||||||||||||
| WW | 212 | 256 | (17.3) | (16.2) | (1.1) | ||||||||||||||||||
| PULMONARY HYPERTENSION (PH) | |||||||||||||||||||||||
| US | 588 | 815 | (27.8) | (27.8) | — | ||||||||||||||||||
| Intl | 309 | 300 | 2.9 | 4.1 | (1.2) | ||||||||||||||||||
| WW | 897 | 1,115 | (19.5) | (19.2) | (0.3) | ||||||||||||||||||
| UPTRAVI | |||||||||||||||||||||||
| US | 383 | 392 | (2.2) | (2.2) | — | ||||||||||||||||||
| Intl | 100 | 92 | 8.9 | 8.4 | 0.5 | ||||||||||||||||||
| WW | 483 | 484 | (0.1) | (0.2) | 0.1 | ||||||||||||||||||
| OPSUMIT / OPSYNVI | |||||||||||||||||||||||
| US | 193 | 409 | (52.8) | (52.8) | — | ||||||||||||||||||
| Intl | 179 | 168 | 5.9 | 7.8 | (1.9) | ||||||||||||||||||
| WW | 372 | 578 | (35.7) | (35.2) | (0.5) | ||||||||||||||||||
| OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||
| US | 12 | 13 | (7.3) | (7.3) | — | ||||||||||||||||||
| Intl | 30 | 39 | (23.8) | (21.2) | (2.6) | ||||||||||||||||||
| WW | 42 | 53 | (19.7) | (17.7) | (2.0) | ||||||||||||||||||
| INFECTIOUS DISEASES (ID) | |||||||||||||||||||||||
| US | 317 | 326 | (2.7) | (2.7) | — | ||||||||||||||||||
| Intl | 496 | 501 | (1.2) | (0.1) | (1.1) | ||||||||||||||||||
| WW | 813 | 829 | (1.8) | (1.1) | (0.7) | ||||||||||||||||||
| EDURANT / rilpivirine | |||||||||||||||||||||||
| US | 5 | 7 | (31.6) | (31.6) | — | ||||||||||||||||||
| Intl | 382 | 378 | 1.0 | 2.4 | (1.4) | ||||||||||||||||||
| WW | 386 | 385 | 0.4 | 1.8 | (1.4) | ||||||||||||||||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||
| US | 307 | 315 | (2.5) | (2.5) | — | ||||||||||||||||||
| Intl | 74 | 81 | (8.9) | (7.7) | (1.2) | ||||||||||||||||||
| WW | 381 | 397 | (3.8) | (3.6) | (0.2) | ||||||||||||||||||
| OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||
| US | 5 | 4 | 29.9 | 29.9 | — | ||||||||||||||||||
| Intl | 40 | 42 | (6.2) | (7.9) | 1.7 | ||||||||||||||||||
| WW | 46 | 47 | (3.0) | (4.5) | 1.5 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CARDIOVASCULAR / METABOLISM / OTHER (CVM) | |||||||||||||||||||||||
| US | $ | 736 | 750 | (1.9) | % | (1.9) | % | — | % | ||||||||||||||
| Intl | 112 | 149 | (24.3) | (23.8) | (0.5) | ||||||||||||||||||
| WW | 849 | 899 | (5.6) | (5.5) | (0.1) | ||||||||||||||||||
| XARELTO | |||||||||||||||||||||||
| US | 653 | 635 | 2.7 | 2.7 | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 653 | 635 | 2.7 | 2.7 | — | ||||||||||||||||||
| OTHER | |||||||||||||||||||||||
| US | 84 | 115 | (27.2) | (27.2) | — | ||||||||||||||||||
| Intl | 112 | 149 | (24.3) | (23.8) | (0.5) | ||||||||||||||||||
| WW | 197 | 264 | (25.5) | (25.3) | (0.2) | ||||||||||||||||||
| TOTAL PH, ID, CVM | |||||||||||||||||||||||
| US | 1,643 | 1,891 | (13.2) | (13.2) | — | ||||||||||||||||||
| Intl | 917 | 950 | (3.5) | (2.5) | (1.0) | ||||||||||||||||||
| WW | 2,560 | 2,843 | (9.9) | (9.6) | (0.3) | ||||||||||||||||||
| TOTAL INNOVATIVE MEDICINE | |||||||||||||||||||||||
| US | 10,447 | 9,402 | 11.1 | 11.1 | — | ||||||||||||||||||
| Intl | 6,310 | 6,161 | 2.4 | 3.0 | (0.6) | ||||||||||||||||||
| WW | $16,757 | 15,563 | 7.7 | % | 7.9 | % | (0.2) | % | |||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2) | |||||||||||||||||||||||
| CARDIOVASCULAR | |||||||||||||||||||||||
| US | $ | 1,397 | 1,306 | 7.0 | % | 7.0 | % | — | % | ||||||||||||||
| Intl | 910 | 908 | 0.2 | (0.2) | 0.4 | ||||||||||||||||||
| WW | 2,307 | 2,213 | 4.3 | 4.1 | 0.2 | ||||||||||||||||||
| ELECTROPHYSIOLOGY | |||||||||||||||||||||||
| US | 771 | 720 | 7.0 | 7.0 | — | ||||||||||||||||||
| Intl | 717 | 698 | 2.8 | 1.8 | 1.0 | ||||||||||||||||||
| WW | 1,487 | 1,418 | 4.9 | 4.4 | 0.5 | ||||||||||||||||||
| ABIOMED | |||||||||||||||||||||||
| US | 335 | 336 | (0.3) | (0.3) | — | ||||||||||||||||||
| Intl | 78 | 86 | (10.4) | (6.5) | (3.9) | ||||||||||||||||||
| WW | 412 | 423 | (2.3) | (1.5) | (0.8) | ||||||||||||||||||
| SHOCKWAVE | |||||||||||||||||||||||
| US | 261 | 220 | 18.8 | 18.8 | — | ||||||||||||||||||
| Intl | 64 | 59 | 9.3 | 11.2 | (1.9) | ||||||||||||||||||
| WW | 325 | 278 | 16.8 | 17.2 | (0.4) | ||||||||||||||||||
| OTHER CARDIOVASCULAR | |||||||||||||||||||||||
| US | 31 | 30 | 3.6 | 3.6 | — | ||||||||||||||||||
| Intl | 50 | 65 | (21.9) | (23.1) | 1.2 | ||||||||||||||||||
| WW | 81 | 95 | (13.9) | (14.7) | 0.8 | ||||||||||||||||||
| SURGERY | |||||||||||||||||||||||
| US | 1,070 | 1,031 | 3.7 | 3.7 | — | ||||||||||||||||||
| Intl | 1,459 | 1,511 | (3.4) | (4.2) | 0.8 | ||||||||||||||||||
| WW | 2,528 | 2,542 | (0.6) | (1.0) | 0.4 | ||||||||||||||||||
| ADVANCED | |||||||||||||||||||||||
| US | 500 | 477 | 5.1 | 5.1 | — | ||||||||||||||||||
| Intl | 654 | 688 | (5.0) | (5.7) | 0.7 | ||||||||||||||||||
| WW | 1,155 | 1,165 | (0.9) | (1.3) | 0.4 | ||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| US | 568 | 555 | 2.4 | 2.4 | — | ||||||||||||||||||
| Intl | 805 | 823 | (2.2) | (3.0) | 0.8 | ||||||||||||||||||
| WW | 1,373 | 1,378 | (0.3) | (0.8) | 0.5 | ||||||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| THIRD QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2)(Continued) | |||||||||||||||||||||||
| VISION | |||||||||||||||||||||||
| US | $596 | 571 | 4.3 | % | 4.3 | % | — | % | |||||||||||||||
| Intl | 865 | 828 | 4.4 | 5.6 | (1.2) | ||||||||||||||||||
| WW | 1,461 | 1,400 | 4.4 | 5.1 | (0.7) | ||||||||||||||||||
| CONTACT LENSES / OTHER | |||||||||||||||||||||||
| US | 465 | 456 | 1.9 | 1.9 | — | ||||||||||||||||||
| Intl | 588 | 562 | 4.7 | 6.2 | (1.5) | ||||||||||||||||||
| WW | 1,053 | 1,018 | 3.5 | 4.3 | (0.8) | ||||||||||||||||||
| SURGICAL | |||||||||||||||||||||||
| US | 132 | 116 | 13.6 | 13.6 | — | ||||||||||||||||||
| Intl | 276 | 266 | 3.8 | 4.3 | (0.5) | ||||||||||||||||||
| WW | 408 | 383 | 6.8 | 7.1 | (0.3) | ||||||||||||||||||
| ORTHOPAEDICS | |||||||||||||||||||||||
| US | 1,448 | 1,396 | 3.8 | 3.8 | — | ||||||||||||||||||
| Intl | 898 | 878 | 2.2 | 2.9 | (0.7) | ||||||||||||||||||
| WW | 2,345 | 2,274 | 3.2 | 3.4 | (0.2) | ||||||||||||||||||
| HIPS | |||||||||||||||||||||||
| US | 271 | 262 | 3.5 | 3.5 | — | ||||||||||||||||||
| Intl | 148 | 144 | 2.6 | 3.0 | (0.4) | ||||||||||||||||||
| WW | 419 | 405 | 3.1 | 3.3 | (0.2) | ||||||||||||||||||
| KNEES | |||||||||||||||||||||||
| US | 221 | 216 | 2.1 | 2.1 | — | ||||||||||||||||||
| Intl | 165 | 160 | 3.0 | 4.4 | (1.4) | ||||||||||||||||||
| WW | 386 | 377 | 2.5 | 3.1 | (0.6) | ||||||||||||||||||
| TRAUMA | |||||||||||||||||||||||
| US | 555 | 512 | 8.6 | 8.6 | — | ||||||||||||||||||
| Intl | 288 | 281 | 2.4 | 2.8 | (0.4) | ||||||||||||||||||
| WW | 844 | 793 | 6.4 | 6.5 | (0.1) | ||||||||||||||||||
| SPINE, SPORTS & OTHER | |||||||||||||||||||||||
| US | 401 | 406 | (1.2) | (1.2) | — | ||||||||||||||||||
| Intl | 296 | 293 | 1.3 | 2.0 | (0.7) | ||||||||||||||||||
| WW | 697 | 698 | (0.1) | 0.1 | (0.2) | ||||||||||||||||||
| TOTAL MEDTECH | |||||||||||||||||||||||
| US | 4,512 | 4,306 | 4.8 | 4.8 | — | ||||||||||||||||||
| Intl | 4,130 | 4,124 | 0.1 | 0.1 | 0.0 | ||||||||||||||||||
| WW | $8,642 | 8,430 | 2.5 | % | 2.5 | % | 0.0 | % | |||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2) | |||||||||||||||||||||||
| ONCOLOGY | |||||||||||||||||||||||
| US | $11,951 | 9,866 | 21.1 | % | 21.1 | % | — | % | |||||||||||||||
| Intl | 10,030 | 8,652 | 15.9 | 11.9 | 4.0 | ||||||||||||||||||
| WW | 21,981 | 18,519 | 18.7 | 16.8 | 1.9 | ||||||||||||||||||
| DARZALEX | |||||||||||||||||||||||
| US | 7,171 | 5,934 | 20.9 | 20.9 | — | ||||||||||||||||||
| Intl | 5,239 | 4,514 | 16.1 | 11.9 | 4.2 | ||||||||||||||||||
| WW | 12,410 | 10,448 | 18.8 | 17.0 | 1.8 | ||||||||||||||||||
| CARVYKTI | |||||||||||||||||||||||
| US | 1,377 | 1,072 | 28.5 | 28.5 | — | ||||||||||||||||||
| Intl | 587 | 260 | * | * | * | ||||||||||||||||||
| WW | 1,964 | 1,332 | 47.4 | 45.5 | 1.9 | ||||||||||||||||||
| TECVAYLI | |||||||||||||||||||||||
| US | 549 | 334 | 64.4 | 64.4 | — | ||||||||||||||||||
| Intl | 225 | 160 | 40.6 | 37.7 | 2.9 | ||||||||||||||||||
| WW | 774 | 494 | 56.7 | 55.7 | 1.0 | ||||||||||||||||||
| TALVEY | |||||||||||||||||||||||
| US | 325 | 235 | 38.1 | 38.1 | — | ||||||||||||||||||
| Intl | 172 | 79 | * | * | * | ||||||||||||||||||
| WW | 497 | 314 | 58.3 | 57.5 | 0.8 | ||||||||||||||||||
| RYBREVANT / LAZCLUZE | |||||||||||||||||||||||
| US | 566 | 388 | 46.1 | 46.1 | — | ||||||||||||||||||
| Intl | 300 | 130 | * | * | * | ||||||||||||||||||
| WW | 866 | 518 | 67.4 | 67.5 | (0.1) | ||||||||||||||||||
| ERLEADA | |||||||||||||||||||||||
| US | 1,161 | 1,048 | 10.8 | 10.8 | — | ||||||||||||||||||
| Intl | 1,806 | 1,567 | 15.3 | 10.8 | 4.5 | ||||||||||||||||||
| WW | 2,967 | 2,615 | 13.5 | 10.8 | 2.7 | ||||||||||||||||||
| IMBRUVICA | |||||||||||||||||||||||
| US | 437 | 685 | (36.3) | (36.3) | — | ||||||||||||||||||
| Intl | 1,386 | 1,453 | (4.7) | (8.7) | 4.0 | ||||||||||||||||||
| WW | 1,822 | 2,139 | (14.8) | (17.5) | 2.7 | ||||||||||||||||||
OTHER ONCOLOGY(3) | |||||||||||||||||||||||
| US | 365 | 171 | * | * | — | ||||||||||||||||||
| Intl | 314 | 488 | (35.7) | (36.0) | 0.3 | ||||||||||||||||||
| WW | 680 | 659 | 3.2 | 2.9 | 0.3 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| IMMUNOLOGY | |||||||||||||||||||||||
| US | $7,031 | 7,377 | (4.7) | % | (4.7) | % | — | % | |||||||||||||||
| Intl | 4,414 | 4,492 | (1.7) | (4.9) | 3.2 | ||||||||||||||||||
| WW | 11,445 | 11,868 | (3.6) | (4.8) | 1.2 | ||||||||||||||||||
| TREMFYA | |||||||||||||||||||||||
| US | 4,279 | 2,384 | 79.5 | 79.5 | — | ||||||||||||||||||
| Intl | 1,771 | 1,181 | 49.9 | 44.7 | 5.2 | ||||||||||||||||||
| WW | 6,050 | 3,566 | 69.7 | 67.9 | 1.8 | ||||||||||||||||||
| SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||
| US | 798 | 906 | (11.9) | (11.9) | — | ||||||||||||||||||
| Intl | 1,035 | 1,130 | (8.4) | (11.4) | 3.0 | ||||||||||||||||||
| WW | 1,833 | 2,036 | (10.0) | (11.6) | 1.6 | ||||||||||||||||||
| REMICADE | |||||||||||||||||||||||
| US | 742 | 923 | (19.6) | (19.6) | — | ||||||||||||||||||
US Exports(4) | 40 | 63 | (36.6) | (36.6) | — | ||||||||||||||||||
| Intl | 372 | 413 | (9.8) | (12.9) | 3.1 | ||||||||||||||||||
| WW | 1,154 | 1,398 | (17.5) | (18.4) | 0.9 | ||||||||||||||||||
| STELARA | |||||||||||||||||||||||
| US | 924 | 3,081 | (70.0) | (70.0) | — | ||||||||||||||||||
| Intl | 1,188 | 1,768 | (32.8) | (34.9) | 2.1 | ||||||||||||||||||
| WW | 2,112 | 4,848 | (56.4) | (57.2) | 0.8 | ||||||||||||||||||
| OTHER IMMUNOLOGY | |||||||||||||||||||||||
| US | 249 | 21 | * | * | — | ||||||||||||||||||
| Intl | 48 | 0 | * | * | * | ||||||||||||||||||
| WW | 297 | 21 | * | * | * | ||||||||||||||||||
| NEUROSCIENCE | |||||||||||||||||||||||
| US | 4,886 | 3,712 | 31.6 | 31.6 | — | ||||||||||||||||||
| Intl | 2,001 | 2,011 | (0.5) | (3.0) | 2.5 | ||||||||||||||||||
| WW | 6,887 | 5,722 | 20.3 | 19.5 | 0.8 | ||||||||||||||||||
| SPRAVATO | |||||||||||||||||||||||
| US | 1,479 | 1,047 | 41.3 | 41.3 | — | ||||||||||||||||||
| Intl | 197 | 146 | 34.8 | 28.1 | 6.7 | ||||||||||||||||||
| WW | 1,676 | 1,193 | 40.5 | 39.7 | 0.8 | ||||||||||||||||||
CAPLYTA(5) | |||||||||||||||||||||||
| US | 1,029 | 451 | * | * | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 1,029 | 451 | * | * | — | ||||||||||||||||||
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||
| US | 2,235 | 2,021 | 10.6 | 10.6 | — | ||||||||||||||||||
| Intl | 816 | 804 | 1.5 | (0.8) | 2.3 | ||||||||||||||||||
| WW | 3,051 | 2,824 | 8.0 | 7.4 | 0.6 | ||||||||||||||||||
| CONCERTA / methylphenidate | |||||||||||||||||||||||
| US | 40 | 76 | (47.3) | (47.3) | — | ||||||||||||||||||
| Intl | 386 | 376 | 2.4 | 1.1 | 1.3 | ||||||||||||||||||
| WW | 425 | 452 | (5.9) | (7.0) | 1.1 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| OTHER NEUROSCIENCE | |||||||||||||||||||||||
| US | $ | 104 | 119 | (12.6) | % | (12.6) | % | — | % | ||||||||||||||
| Intl | 602 | 684 | (12.0) | (14.5) | 2.5 | ||||||||||||||||||
| WW | 706 | 803 | (12.1) | (14.2) | 2.1 | ||||||||||||||||||
| PULMONARY HYPERTENSION (PH) | |||||||||||||||||||||||
| US | 2,233 | 2,358 | (5.3) | (5.3) | — | ||||||||||||||||||
| Intl | 942 | 895 | 5.2 | 2.9 | 2.3 | ||||||||||||||||||
| WW | 3,175 | 3,253 | (2.4) | (3.0) | 0.6 | ||||||||||||||||||
| UPTRAVI | |||||||||||||||||||||||
| US | 1,154 | 1,139 | 1.3 | 1.3 | — | ||||||||||||||||||
| Intl | 306 | 272 | 12.7 | 7.9 | 4.8 | ||||||||||||||||||
| WW | 1,460 | 1,411 | 3.5 | 2.6 | 0.9 | ||||||||||||||||||
| OPSUMIT / OPSYNVI | |||||||||||||||||||||||
| US | 1,042 | 1,175 | (11.3) | (11.3) | — | ||||||||||||||||||
| Intl | 538 | 507 | 6.0 | 4.4 | 1.6 | ||||||||||||||||||
| WW | 1,580 | 1,682 | (6.1) | (6.6) | 0.5 | ||||||||||||||||||
| OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||
| US | 37 | 44 | (15.5) | (15.5) | — | ||||||||||||||||||
| Intl | 98 | 116 | (15.6) | (15.3) | (0.3) | ||||||||||||||||||
| WW | 135 | 160 | (15.6) | (15.4) | (0.2) | ||||||||||||||||||
| INFECTIOUS DISEASES (ID) | |||||||||||||||||||||||
| US | 959 | 961 | (0.2) | (0.2) | — | ||||||||||||||||||
| Intl | 1,506 | 1,472 | 2.3 | (1.7) | 4.0 | ||||||||||||||||||
| WW | 2,465 | 2,434 | 1.3 | (1.1) | 2.4 | ||||||||||||||||||
| EDURANT / rilpivirine | |||||||||||||||||||||||
| US | 15 | 21 | (30.1) | (30.1) | — | ||||||||||||||||||
| Intl | 1,131 | 1,082 | 4.5 | 0.6 | 3.9 | ||||||||||||||||||
| WW | 1,145 | 1,103 | 3.8 | 0.0 | 3.8 | ||||||||||||||||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||
| US | 937 | 932 | 0.6 | 0.6 | — | ||||||||||||||||||
| Intl | 259 | 264 | (1.9) | (6.2) | 4.3 | ||||||||||||||||||
| WW | 1,196 | 1,196 | 0.0 | (0.9) | 0.9 | ||||||||||||||||||
| OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||
| US | 7 | 8 | (11.4) | (11.4) | — | ||||||||||||||||||
| Intl | 116 | 126 | (8.0) | (11.7) | 3.7 | ||||||||||||||||||
| WW | 124 | 135 | (8.2) | (11.7) | 3.5 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CARDIOVASCULAR / METABOLISM / OTHER (CVM) | |||||||||||||||||||||||
| US | $ | 2,235 | 2,381 | (6.1) | % | (6.1) | % | — | % | ||||||||||||||
| Intl | 378 | 461 | (17.9) | (20.9) | 3.0 | ||||||||||||||||||
| WW | 2,614 | 2,842 | (8.0) | (8.5) | 0.5 | ||||||||||||||||||
| XARELTO | |||||||||||||||||||||||
| US | 1,959 | 1,946 | 0.7 | 0.7 | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 1,959 | 1,946 | 0.7 | 0.7 | — | ||||||||||||||||||
| OTHER | |||||||||||||||||||||||
| US | 276 | 435 | (36.5) | (36.5) | — | ||||||||||||||||||
| Intl | 378 | 461 | (17.9) | (20.9) | 3.0 | ||||||||||||||||||
| WW | 655 | 896 | (26.9) | (28.5) | 1.6 | ||||||||||||||||||
| TOTAL PH, ID, CVM | |||||||||||||||||||||||
| US | 5,428 | 5,700 | (4.8) | (4.8) | — | ||||||||||||||||||
| Intl | 2,826 | 2,828 | (0.1) | (3.4) | 3.3 | ||||||||||||||||||
| WW | 8,254 | 8,529 | (3.2) | (4.3) | 1.1 | ||||||||||||||||||
| TOTAL INNOVATIVE MEDICINE | |||||||||||||||||||||||
| US | 29,297 | 26,655 | 9.9 | 9.9 | — | ||||||||||||||||||
| Intl | 19,270 | 17,983 | 7.2 | 3.6 | 3.6 | ||||||||||||||||||
| WW | $ | 48,567 | 44,638 | 8.8 | % | 7.4 | % | 1.4 | % | ||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2) | |||||||||||||||||||||||
| CARDIOVASCULAR | |||||||||||||||||||||||
| US | $ | 4,222 | 3,931 | 7.4 | % | 7.4 | % | — | % | ||||||||||||||
| Intl | 2,866 | 2,698 | 6.2 | 3.4 | 2.8 | ||||||||||||||||||
| WW | 7,088 | 6,629 | 6.9 | 5.8 | 1.1 | ||||||||||||||||||
| ELECTROPHYSIOLOGY | |||||||||||||||||||||||
| US | 2,290 | 2,145 | 6.8 | 6.8 | — | ||||||||||||||||||
| Intl | 2,219 | 2,064 | 7.5 | 4.3 | 3.2 | ||||||||||||||||||
| WW | 4,509 | 4,209 | 7.1 | 5.6 | 1.5 | ||||||||||||||||||
| ABIOMED | |||||||||||||||||||||||
| US | 1,066 | 1,035 | 3.0 | 3.0 | — | ||||||||||||||||||
| Intl | 275 | 256 | 7.2 | 5.4 | 1.8 | ||||||||||||||||||
| WW | 1,340 | 1,291 | 3.8 | 3.5 | 0.3 | ||||||||||||||||||
| SHOCKWAVE | |||||||||||||||||||||||
| US | 771 | 659 | 17.0 | 17.0 | — | ||||||||||||||||||
| Intl | 194 | 169 | 14.8 | 15.1 | (0.3) | ||||||||||||||||||
| WW | 965 | 828 | 16.6 | 16.6 | 0.0 | ||||||||||||||||||
| OTHER CARDIOVASCULAR | |||||||||||||||||||||||
| US | 96 | 93 | 3.2 | 3.2 | — | ||||||||||||||||||
| Intl | 177 | 209 | (15.0) | (17.7) | 2.7 | ||||||||||||||||||
| WW | 273 | 302 | (9.4) | (11.3) | 1.9 | ||||||||||||||||||
| SURGERY | |||||||||||||||||||||||
| US | 3,210 | 3,076 | 4.3 | 4.3 | — | ||||||||||||||||||
| Intl | 4,483 | 4,417 | 1.5 | (1.6) | 3.1 | ||||||||||||||||||
| WW | 7,692 | 7,493 | 2.7 | 0.8 | 1.9 | ||||||||||||||||||
| ADVANCED | |||||||||||||||||||||||
| US | 1,476 | 1,411 | 4.7 | 4.7 | — | ||||||||||||||||||
| Intl | 1,991 | 1,991 | 0.0 | (2.9) | 2.9 | ||||||||||||||||||
| WW | 3,467 | 3,402 | 1.9 | 0.2 | 1.7 | ||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| US | 1,733 | 1,666 | 4.0 | 4.0 | — | ||||||||||||||||||
| Intl | 2,492 | 2,426 | 2.7 | (0.6) | 3.3 | ||||||||||||||||||
| WW | 4,225 | 4,092 | 3.3 | 1.3 | 2.0 | ||||||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| NINE MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2)(Continued) | |||||||||||||||||||||||
| VISION | |||||||||||||||||||||||
| US | $1,740 | 1,694 | 2.7 | % | 2.7 | % | — | % | |||||||||||||||
| Intl | 2,537 | 2,354 | 7.8 | 6.3 | 1.5 | ||||||||||||||||||
| WW | 4,277 | 4,048 | 5.6 | 4.8 | 0.8 | ||||||||||||||||||
| CONTACT LENSES / OTHER | |||||||||||||||||||||||
| US | 1,378 | 1,337 | 3.1 | 3.1 | — | ||||||||||||||||||
| Intl | 1,669 | 1,565 | 6.6 | 5.5 | 1.1 | ||||||||||||||||||
| WW | 3,047 | 2,902 | 5.0 | 4.4 | 0.6 | ||||||||||||||||||
| SURGICAL | |||||||||||||||||||||||
| US | 363 | 358 | 1.4 | 1.4 | — | ||||||||||||||||||
| Intl | 867 | 789 | 10.0 | 8.0 | 2.0 | ||||||||||||||||||
| WW | 1,230 | 1,147 | 7.3 | 5.9 | 1.4 | ||||||||||||||||||
| ORTHOPAEDICS | |||||||||||||||||||||||
| US | 4,353 | 4,200 | 3.6 | 3.6 | — | ||||||||||||||||||
| Intl | 2,794 | 2,620 | 6.6 | 3.5 | 3.1 | ||||||||||||||||||
| WW | 7,146 | 6,820 | 4.8 | 3.6 | 1.2 | ||||||||||||||||||
| HIPS | |||||||||||||||||||||||
| US | 831 | 796 | 4.4 | 4.4 | — | ||||||||||||||||||
| Intl | 465 | 440 | 5.7 | 2.1 | 3.6 | ||||||||||||||||||
| WW | 1,296 | 1,235 | 4.9 | 3.6 | 1.3 | ||||||||||||||||||
| KNEES | |||||||||||||||||||||||
| US | 688 | 673 | 2.2 | 2.2 | — | ||||||||||||||||||
| Intl | 528 | 482 | 9.7 | 7.1 | 2.6 | ||||||||||||||||||
| WW | 1,216 | 1,155 | 5.3 | 4.2 | 1.1 | ||||||||||||||||||
| TRAUMA | |||||||||||||||||||||||
| US | 1,623 | 1,515 | 7.1 | 7.1 | — | ||||||||||||||||||
| Intl | 880 | 818 | 7.6 | 4.4 | 3.2 | ||||||||||||||||||
| WW | 2,504 | 2,333 | 7.3 | 6.2 | 1.1 | ||||||||||||||||||
| SPINE, SPORTS & OTHER | |||||||||||||||||||||||
| US | 1,211 | 1,216 | (0.4) | (0.4) | — | ||||||||||||||||||
| Intl | 920 | 881 | 4.5 | 1.5 | 3.0 | ||||||||||||||||||
| WW | 2,131 | 2,096 | 1.7 | 0.4 | 1.3 | ||||||||||||||||||
| TOTAL MEDTECH | |||||||||||||||||||||||
| US | 13,525 | 12,902 | 4.8 | 4.8 | — | ||||||||||||||||||
| Intl | 12,679 | 12,089 | 4.9 | 2.2 | 2.7 | ||||||||||||||||||
| WW | $26,204 | 24,991 | 4.9 | % | 3.5 | % | 1.4 | % | |||||||||||||||
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1)Operational growth excludes the effect of translational currency
(2)Unaudited
(3)Includes the sales of ZYTIGA which were previously disclosed separately
(4)Reported as U.S. sales
(5)Acquired with Intra-Cellular Therapies on April 2, 2025